Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.
Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.
Atea Pharmaceuticals (AVIR) has initiated the SUNRISE-3 Phase 3 trial to evaluate bemnifosbuvir, an oral antiviral treatment for COVID-19, in high-risk non-hospitalized patients. The trial aims to enroll at least 1,500 participants and will assess its efficacy against hospitalization and death. Bemnifosbuvir targets the SARS-CoV-2 RNA polymerase, boasting a unique mechanism that helps mitigate resistance. Previous late-stage trials indicated a 71% reduction in hospitalization rates for treated patients compared to placebo. This development highlights Atea's focus on unmet medical needs in COVID-19 treatment.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi and the management team will present a business update at the 5th Annual Evercore ISI HealthCONx Conference on November 29 at 9:40 a.m. ET. A live webcast will be available on the company’s website, with an archived version accessible for 90 days post-event.
Atea focuses on developing oral antiviral therapies for severe diseases, including COVID-19, hepatitis C, and dengue, leveraging its nucleos(t)ide prodrug platform to address unmet medical needs.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a business update at the Jefferies London Healthcare Conference on November 15, 2022, at 5:00 p.m. GMT / 12:00 p.m. ET. The event will be accessible via a live webcast and archived for 90 days post-event. Atea focuses on developing oral therapies for severe viral infections, leveraging its nucleos(t)ide prodrug platform. Current efforts include targeting COVID-19, hepatitis C, and other severe viral diseases.
Atea Pharmaceuticals (Nasdaq: AVIR) announced key updates and financial results for Q3 2022, reporting a net loss of $8.1 million, down from a loss of $28.2 million in 2021. The company holds $665 million in cash and marketable securities. Notably, the SUNRISE-3 trial for bemnifosbuvir in high-risk COVID-19 patients is set to enroll before year-end 2022. Additionally, Atea plans to submit trial applications for a hepatitis C combination study. Research and development expenses decreased significantly, attributed to the termination of a cost-sharing agreement with Roche.
Atea Pharmaceuticals (AVIR) provided updates on AT-752, an oral antiviral for dengue fever, during the ASTMH 2022 Annual Meeting. The Phase 1 trial showed that AT-752 was well tolerated at doses up to 1500 mg, achieving plasma levels above the in vitro EC90. The FDA has given Fast Track designation for AT-752, making it a promising option for treating dengue, which affects 400 million annually. Atea is advancing two proof-of-concept studies to evaluate AT-752's safety and efficacy against dengue, aiming to fill the existing treatment gap.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a live conference call on November 7, 2022, at 4:30 p.m. ET, to report financial results for Q3 2022 and provide a business update. The call can be accessed via registration, with a webcast available in the Investor Relations section of the company's website. Atea focuses on developing oral therapies for severe diseases, particularly targeting ssRNA viruses, including SARS-CoV-2, HCV, dengue, and RSV. The company aims to expand its antiviral pipeline through its proprietary nucleos(t)ide prodrug platform.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that the FDA granted Fast Track Designation to AT-752, an oral antiviral for dengue treatment. This designation aims to expedite development, acknowledging the urgent need for effective treatments as there are currently no approved options. AT-752 has shown promising preclinical activity against dengue and safety in Phase 1 trials. The company is advancing two Phase 2 studies to assess AT-752’s efficacy and safety in adults with dengue virus infections, with initial data expected soon.
Atea Pharmaceuticals (Nasdaq: AVIR) announced a global Phase 3 trial to assess bemnifosbuvir for COVID-19, beginning in Q4 2022. The trial targets high-risk non-hospitalized patients, evaluating bemnifosbuvir as both monotherapy and in combination with other treatments. Previous trials indicated a 71% reduction in hospitalization rates. The randomized, double-blind study aims to enroll 1,500 patients across 300 sites worldwide, focusing on safety and efficacy against various COVID-19 variants. Positive early results emphasize bemnifosbuvir's potential as a cornerstone therapy for COVID-19 treatment.
Atea Pharmaceuticals (Nasdaq: AVIR) announced participation in key investor events on September 13, 2022. The management will host a conference call at 8:30 a.m. ET to detail the global Phase 3 trial of bemnifosbuvir for COVID-19 treatment. Additionally, CEO Jean-Pierre Sommadossi will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 12:55 p.m. ET. Live webcasts of these events will be available on Atea's website.
Atea Pharmaceuticals (AVIR) is advancing bemnifosbuvir into late-stage clinical trials for COVID-19 after discussions with the FDA and EMA. New data show bemnifosbuvir retains antiviral activity against the Omicron variant. The company is also enrolling in Phase 2 trials for dengue and preparing for a Phase 2 trial for HCV. Financially, Atea reported a net loss of $31.3 million for Q2 2022, a significant drop from a net income of $1.5 million in Q2 2021, driven by the loss of collaboration revenue from Roche.